BLAINJECTIONINJECTABLEPriority Review
Approved
Sep 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) by Merck & Co. is programmed death receptor-1-directed antibody interactions [moa]. Approved for programmed death receptor-1 blocking antibody [epc]. First approved in 2025.
Drug data last refreshed 26m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KEYTRUDA QLEX is a fixed-dose combination of pembrolizumab (a PD-1 inhibitor) and berahyaluronidase alfa, a recombinant human hyaluronidase enzyme that enables subcutaneous administration. It harnesses immune checkpoint inhibition to block the PD-1 pathway, unleashing anti-tumor T-cell responses across multiple cancer indications. The hyaluronidase component allows for subcutaneous delivery, improving convenience and potentially expanding access compared to intravenous pembrolizumab.
Launch
Recent launch with moderate competitive intensity (30/100) positions the team to capture share from the dominant intravenous pembrolizumab formulation; commercial infrastructure already established through parent KEYTRUDA enables faster uptake.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on KEYTRUDA QLEX offers the rare career opportunity to drive conversion of an established blockbuster from IV to subcutaneous dosing—a playbook increasingly valued across oncology and specialty care. Teams will focus on clinician education, patient support program optimization, and payer negotiation on the convenience and compliance value proposition, positioning early career talent for cross-functional launch leadership and market access expertise.
Brand Manager
Worked on KEYTRUDA QLEX at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.